Trial intelligence / Profile preview

Phase Ib/II trial of BEBT-908 and BEBT-109 in advanced EGFR-mutant NSCLC after third-generation EGFR-TKI

ChiCTR2100054223Phase 2Recruiting

Sponsor

Hunan Cancer Hospital

Start

Dec 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1